30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

2014 Revenue: Medicrea

€24.2MM (~US $28.49MM), +6%

  • In 1H14, sales growth in American and French markets offset by temporary import issues in Brazil
  • In 2H14, growth supported by U.S. development and effects of new international sales teams
  • U.S. (the group's priority market) represents >60% of sales
  • Will maintain high level of R&D investment into 2015
  • Discussions underway with "several American groups" on exclusive use of K-JAWS in the U.S., with an option for rest of world